About Klinikum Darmstadt GmbH; Med. Klinik V; Onkologie & Hämatologie
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Hoffmann-La Roche
3
University of Heidelberg Medical Center
2
Clinical Trials at Klinikum Darmstadt GmbH; Med. Klinik V; Onkologie & Hämatologie
During the past decade, Klinikum Darmstadt GmbH; Med. Klinik V; Onkologie & Hämatologie conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 3 clinical trials were completed, i.e. on
average, 150% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)
2010-01-26
2017-08-07
Completed
452
A Study of Rituximab (MabThera) Subcutaneous (SC) Versus Rituximab (MabThera) Intravenous in Participannts With Follicular Non-Hodgkin's Lymphoma
2011-02-15
2017-10-31
Completed
410
A Study Comparing Maintenance Subcutaneous Rituximab With Observation Only in Participants With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to Rituximab-based Immunochemotherapy Induction and 2-year Maintenance With Subcutaneous Rituximab
2011-12-20
2018-06-02
Completed
692
A Phase III Trial on the Effect of Elotuzumab in VRD Induction /Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma
2015-06-01
2021-06-24
Completed
564
Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7)
2018-10-18
2025-12-01
Active, not recruiting
662
Clinical Trials Sponsors and Collaborators
Clinical Trials Conditions at Klinikum Darmstadt GmbH; Med. Klinik V; Onkologie & Hämatologie
According to Clinical.Site data, the most researched conditions in "Klinikum Darmstadt GmbH; Med. Klinik V; Onkologie & Hämatologie" are
"Multiple Myeloma" (2 trials), "Non-Hodgkin's Lymphoma" (2 trials) and "Breast Cancer" (1 trials). Many other conditions were trialed in "Klinikum Darmstadt GmbH; Med. Klinik V; Onkologie & Hämatologie" in a lesser frequency.
Clinical Trials Intervention Types at Klinikum Darmstadt GmbH; Med. Klinik V; Onkologie & Hämatologie
Most popular intervention types in "Klinikum Darmstadt GmbH; Med. Klinik V; Onkologie & Hämatologie" are "Drug" (5 trials). Other intervention types were less common.
The name of intervention was led by "Bortezomib" (2 trials), "Dexamethasone" (2 trials), "Lenalidomide" (2 trials), "Capecitabine" (1 trials) and "Chemotherapy (Induction Period)" (1 trials). Other intervention names were less common.
Clinical Trials Genders at Klinikum Darmstadt GmbH; Med. Klinik V; Onkologie & Hämatologie
The vast majority of trials in "Klinikum Darmstadt GmbH; Med. Klinik V; Onkologie & Hämatologie" are
4 trials for "All" genders and 1 trials for "Female" genders.
Clinical Trials Status at Klinikum Darmstadt GmbH; Med. Klinik V; Onkologie & Hämatologie
Currently, there are NaN active trials in "Klinikum Darmstadt GmbH; Med. Klinik V; Onkologie & Hämatologie".
undefined are not yet recruiting,
undefined are recruiting,
1 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 4 completed trials in Klinikum Darmstadt GmbH; Med. Klinik V; Onkologie & Hämatologie,
undefined suspended trials,
and undefined terminated clinical trials to date.
Out of the total trials that were conducted in Klinikum Darmstadt GmbH; Med. Klinik V; Onkologie & Hämatologie, 0 "Phase 1"
clinical trials were conducted, 0 "Phase 2" clinical
trials and 5 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 0 trials that are defined as “Not Applicable".